The Patients Your Clinic Is Quietly Losing

Rosacea, melasma and pigmentation, and why the treatments most clinics default to are costing you revenue

Most aesthetic clinics in the UK are leaving real money on the table every week. Not because the demand is not there, but because the patients who need the most help are the ones least likely to get it under one roof.

The patient walks in. She has redness across her cheeks that flushes when she drinks wine or stands near a radiator. Or a band of brown pigmentation across her forehead that came on after her second pregnancy and has not shifted since. Or post-inflammatory marks from the acne she had in her twenties that still show up under foundation.

She does not ask for rosacea treatment, or melasma treatment, or pigmentation treatment. She asks for "something that works". And most clinics, for reasons that make total sense in isolation, cannot give her that in a way she can feel in the mirror.

What clinics currently reach for, and where each one falls down

Topicals

Metronidazole, ivermectin, azelaic acid and oral low-dose doxycycline for rosacea. Hydroquinone, tretinoin, tranexamic acid, kojic acid and products like Cyspera, Obagi and Cosmelan for melasma and general pigmentation.

These work, to a point. The problem is never the pharmacology, it is the timeline. The patient needs to apply the product every night for months before the mirror shows anything worth the effort. Compliance drops. Expectations drift. She stops coming in.

Chemical peels

Glycolic, Jessner's, TCA, and the Cosmelan or Dermamelan programmes for stubborn pigmentation.

Peels can deliver. But downtime is real, and in Fitzpatrick IV to VI skin the risk of post-inflammatory hyperpigmentation is significant enough that a lot of clinicians, rightly, pull back. The patient whose skin most needs the help is often the patient the peel cannot safely be done on.

IPL

The workhorse of rosacea treatment in UK clinics, and a common choice for solar lentigines.

IPL works well within its window. Outside that window it is a problem. Fitzpatrick IV and above is a contraindication in most protocols. In melasma it can trigger rebound that leaves the patient worse than when she arrived. And it sits on a separate device, in a separate room, with separate training.

Vascular and pigment lasers

Vbeam, KTP and Nd:YAG for vascular concerns. Q-switched Nd:YAG and pico devices for pigment.

Clinical results are excellent. The capex is £60,000 to £120,000 per device, and most clinics need more than one to cover the full range of what walks in. The "melasma paradox" is also well documented, where pigment lasers can make melasma worse if the settings are not right.

The pattern

Every clinic ends up with a partial solution. Topicals for the compliant patients. Peels for the straightforward ones with lighter skin. IPL for the rosacea cases that are not too pigmented. And a referral or a shrug for everything else.

The patient you never see come back

The patient who walks out without a clear plan does not usually complain. She just goes somewhere else. Sometimes the clinic down the road with the laser setup. Sometimes to the prescription topicals she will abandon in six weeks. Often she gives up and covers it with makeup.

You are not losing her because of price. You are losing her because you could not answer her question in a way she could see in the mirror.

What Sylfirm X changes

Sylfirm X is an RF microneedling device, and that framing does it a disservice, because most of the RF microneedling category is aimed at skin resurfacing and anti-ageing.

What makes Sylfirm X different is its Pulsed Wave mode, which is designed for vascular and pigmentary conditions. It targets abnormal blood vessels and pigment without damaging the surrounding epidermis, which is why it can be used safely across all Fitzpatrick skin types, including the ones where IPL and pigment lasers carry the most risk.

In practical terms that means:

• Rosacea, melasma and pigmentation can be treated on one device.
• The patient can see a visible change after a single session, with a course of three recommended for durable results.
• The skin types most likely to present with melasma and post-inflammatory pigmentation are the skin types Sylfirm X is safest on, which is the inverse of most existing in-clinic options.
• The clinic stops referring out.

The numbers, honestly

If three patients a week who currently walk out without a treatment plan book a course of three at £1,800, that is around £280,000 a year in revenue the clinic is already generating the demand for. Not new footfall. Not a marketing campaign. Patients who are already in the consultation room.

Sylfirm X is available through Novus Medical on a leasing arrangement, which means the device starts generating revenue before the repayments become significant. For most clinics, treating three of those patients a week covers the lease and leaves margin from session one.

The question worth asking

Walk through the last month of consultations. How many patients presented with rosacea, melasma or pigmentation alongside the usual anti-ageing concerns? How many left with a plan they could believe in, and how many left with a topical recommendation and a vague "let's see how that goes"?

The gap between those two numbers is the opportunity.

Next step

Novus Medical works with UK clinics on Sylfirm X placement, clinical training and finance structure. If it would be useful to see the clinical evidence, the protocols by condition, and an ROI model built around your current patient mix, we can do that in fifteen minutes on a call.

Book a conversation with Jim Westwood at https://meetings-eu1.hubspot.com/jwestwood/intro.

Afeatured in Tatler, Daily Mail, Harper's Bazaar and Vogue.